In normal mice, giving the growth‑hormone‑releasing peptide (sermorelin) quickly spikes GH levels, but in dwarf ‘Little’ mice that have a pituitary defect, the same peptide does nothing and doesn’t boost growth. This shows the peptide only works when the pituitary can store and release GH.

The 'Little' mouse is characterized by a body growth rate 60% of normal due to a defect in the synthesis and storage of GH in the anterior pituitary gland. We have now investigated the effects of GH releasing factor (GRF) in these mice and in normal animals. The pituitary GH content in Little mice was only 4% of that in normal C57: +/+ mice, and was not affected by twice daily i.p. injections of human (h) GRF1-29NH2 (0.2-2 micrograms) for 14 days. This treatment also had no effect on body growth. In anaesthetized normal mice, single i.v. injections of 0.1 or 2 micrograms hGRF1-29NH2 released large amounts of GH into the plasma, whereas this peptide was ineffective in Little mice, whether or not they had been pretreated with GRF. Therefore, although pituitaries of Little mice contain significant amounts of GH, this pool is not releasable by GRF. This suggests that the dwarfism in Little mice may be partly due to a pituitary defect in GRF receptors or their stimulus-secretion coupling, rather than a deficiency in hypothalamic GRF.